Therapeutic targeting of the phosphatidylinositol 3-kinase signaling pathway: Novel targeted therapies and advances in the treatment of colorectal cancer

Therapeutic Advances in Gastroenterology

Volumn 5, Issue 5, 2012, Pages 319-337

  Yu, Ming ^a   Grady, William M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

AKT; Colorectal cancer; PI3 kinase; Signaling; Therapy

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; [1 (4 OXO 8 PHENYL 4H 1 BENZOPYRAN 2 YL)MORPHOLINIO]METHOXYSUCCINYLARGINYLGLYCYLASPARTYLSERINE ACETATE; AMPHIREGULIN; ARRY 438162; BUPARLISIB; CAPECITABINE; CETUXIMAB; CYCLIN DEPENDENT KINASE INHIBITOR 1A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIREGULIN; ERLOTINIB; EVEROLIMUS; GUANOSINE TRIPHOSPHATE; INITIATION FACTOR 4E; IRINOTECAN; K RAS PROTEIN; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOPROTEIN PHOSPHATASE 2A; PICTILISIB; PROTEIN KINASE B; RAC1 PROTEIN; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; XL 765; ZD 8055;

ANTINEOPLASTIC ACTIVITY; CANCER CELL; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; COLORECTAL CANCER; CONSENSUS SEQUENCE; DRUG EFFICACY; DRUG TARGETING; FEEDBACK SYSTEM; GENE MUTATION; GLUCOSE METABOLISM; HETEROZYGOSITY LOSS; HUMAN; MOLECULAR PATHOLOGY; NEGATIVE FEEDBACK; NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POSITIVE FEEDBACK; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SECOND MESSENGER; SIGNAL TRANSDUCTION; VIRUS ONCOGENE;

EID: 84870455331     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X12448456     Document Type: Article

References (138)

1. Baba Y. Nosho K. Shima K. Hayashi M. Meyerhardt J.A. Chan A.T. et al. (2011) Phosphorylated AKT expression is associated with PIK3CA mutation, low stage, and favorable outcome in 717 colorectal cancers. Cancer 117: 1399–1408.
2. Barault L. Veyrie N. Jooste V. Lecorre D. Chapusot C. Ferraz J.M. et al. (2008) Mutations in the RAS-MAPK, PI (3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255–2259.
3. Bayascas J.R. Alessi D.R. (2005) Regulation of Akt/PKB Ser 473 phosphorylation. Mol Cell 18: 143–145.
4. Bendell J.C. Nemunaitis J. Vukelja S.J. Hagenstad C. Campos L.T. Hermann R.C. et al. (2011) Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer. J Clin Oncol 29: 4394–4400.
5. Benistant C. Chapuis H. Roche S. (2000) A specific function for phosphatidylinositol 3-kinase alpha (p85alpha-p110alpha) in cell survival and for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in de novo DNA synthesis of human colon carcinoma cells. Oncogene 19: 5083–5090.
6. Berns K. Horlings H.M. Hennessy B.T. Madiredjo M. Hijmans E.M. Beelen K. et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402.
7. Bjornsti M.A. Houghton P.J. (2004) Lost in translation: dysregulation of cap- dependent translation and cancer. Cancer Cell 5: 519–523.
8. Bos J.L. Fearon E.R. Hamilton S.R. Verlaan-de Vries M. van Boom J.H. van der Eb A.J. et al. (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293–297.
9. Bozulic L. Hemmings B.A. (2009) PIKKing on PKB: regulation of PKB activity by phosphorylation. Curr Opin Cell Biol 21: 256–261.
10. Brunet A. Datta S.R. Greenberg M.E. (2001 a) Transcription-dependent and -independent control of neuronal survival by the PI3K-Akt signaling pathway. Curr Opin Neurobiol 11: 297–305.
11. Brunet A. Park J. Tran H. Hu L.S. Hemmings B.A. Greenberg M.E. (2001 b) Protein kinase SGK mediates survival signals by phosphorylating the forkhead transcription factor FKHRL 1 (FOXO3a). Mol Cell Biol 21: 952–965.
12. Byun D.S. Ahmed N. Nasser S. Shin J. Al-Obaidi S. Goel S. et al. (2011) Intestinal epithelial-specific PTEN inactivation results in tumor formation. Am J Physiol Gastrointest Liver Physiol 301: G856–G864.
13. Cantley L.C. (2002) The phosphoinositide 3-kinase pathway. Science 296: 1655–1657.
14. Carpten J.D. Faber A.L. Horn C. Donoho G.P. Briggs S.L. Robbins C.M. et al. (2007) A transforming mutation in the pleckstrin homology domain of AKT 1 in cancer. Nature 448: 439–444.
15. Carracedo A. Ma L. Teruya-Feldstein J. Rojo F. Salmena L. Alimonti A. et al. (2008) Inhibition of mTORC 1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118: 3065–3074.
16. Carracedo A. Pandolfi P.P. (2008) The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27: 5527–5541.
17. Cervera A. Bernhardt B. Nemunaitis J.J. Ebrahimi B. Birch R. Richards D.A. et al. (2006) Perifosine (P) can be combined with docetaxel (T) without dose reduction of either drug. J Clin Oncol 24(18 Suppl.): 13066.
18. Chowdhury F.U. Shah N. Scarsbrook A.F. Bradley K.M. (2010) [18F] FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J 86: 174–182.
19. Cohen S.J. Punt C.J. Iannotti N. Saidman B.H. Sabbath K.D. Gabrail N.Y. et al. (2009) Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Ann Oncol 20: 1223–1229.
20. Dassonville O. Formento J.L. Francoual M. Ramaioli A. Santini J. Schneider M. et al. (1993) Expression of Epidermal Growth Factor Receptor and Survival in Upper Aerodigestive Tract Cancer. J Clin Oncol 11: 1873–1878.
21. Davies H. Bignell G.R. Cox C. Stephens P. Edkins S. Clegg S. et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954.
22. de Roock W. Claes B. Bernasconi D. de Schutter J. Biesmans B. Fountzilas G. et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753–762.
23. Di Cristofano A. Pandolfi P.P. (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387–390.
24. Di Cristofano A. Pesce B. Cordon-Cardo C. Pandolfi P.P. (1998) Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348–355.
25. Di Nicolantonio F. Arena S. Tabernero J. Grosso S. Molinari F. Macarulla T. et al. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858–2866.
26. Donovan E.A. Kummar S. (2008) Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 66: 91–98.
27. Downward J. (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11–22.
28. Ebi H. Corcoran R.B. Singh A. Chen Z. Song Y. Lifshits E. et al. (2011) Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 121: 4311–4321.
29. Ebrahimi B. Nemunaitis J.J. Shiffman R. Birch R. Diaz-Lacayo M. Berdeaux D.H. et al. (2006) A phase 1 study of daily oral perifosine (P) with weekly paclitaxel (T). J Clin Oncol 24(18 Suppl.): 13117.
30. Edkins S. O'Meara S. Parker A. Stevens C. Reis M. Jones S. et al. (2006) Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 5: 928–932.
31. Engelman J.A. Chen L. Tan X. Crosby K. Guimaraes A.R. Upadhyay R. et al. (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351–1356.
32. Engelman J.A. Janne P.A. (2008) Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895–2899.
33. Engelman J.A. Luo J. Cantley L.C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Rev Genet 7: 606–619.
34. Engelman J.A. Settleman J. (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18: 73–79.
35. Faivre S. Kroemer G. Raymond E. (2006) Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5: 671–688.
36. Fearon E. (1995) Molecular genetics of colorectal cancer. Ann NY Acad Sci 768: 101–110.
37. Feldman M.E. Apsel B. Uotila A. Loewith R. Knight Z.A. Ruggero D. et al. (2009) Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC 1 and mTORC 2. PLoS Biol 7: e38.
38. Foster P.G. (2002) Potentiating the antitumor effects of chemotherapy with the selective PI3K inhibitor XL147. In AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, C199.
39. Fransen K. Klintenas M. Osterstrom A. Dimberg J. Monstein H.J. Soderkvist P. (2004) Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25: 527–533.
40. Frayling I.M. Bodmer W.F. Tomlinson I.P. (1997) Allele loss in colorectal cancer at the Cowden disease/juvenile polyposis locus on 10q. Cancer Genet Cytogenet 97: 64–69.
41. Fujishita T. Aoki K. Lane H.A. Aoki M. Taketo M.M. (2008) Inhibition of the mTORC 1 pathway suppresses intestinal polyp formation and reduces mortality in Apc Delta 716 mice. Proc Natl Acad Sci U S A 105: 13544–13549.
42. Gao T. Furnari F. Newton A.C. (2005) PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18: 13–24.
43. Garcia-Echeverria C. Sellers W.R. (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511–5526.
44. Goel A. Arnold C.N. Niedzwiecki D. Care thers J.M. Dowell J.M. Wasserman L. et al. (2004) Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers. Cancer Res 64: 3014–3021.
45. Goggins T.F. Nemunaitis J.J. Shiffman R. Birch R. Berdeaux D.H. Rettenmaier M. et al. (2006) A phase 1 study of daily oral perifosine (P) with every 3-week paclitaxel (T). J Clin Oncol 24(18 Suppl.): 13134.
46. Grady W.M. Tewari M. (2010) The next thing in prognostic molecular markers: micro RNA signatures of cancer. Gut 59: 706–708.
47. Guertin D.A. Sabatini D.M. (2007) Defining the role of mTOR in cancer. Cancer Cell 12: 9–22.
48. Guix M. Faber A.C. Wang S.E. Olivares M.G. Song Y. Qu S. et al. (2008) Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609–2619.
49. Gullick W.J. (1998) Type I growth factor receptors: current status and future work. Biochem Soc Symp 63: 193–198.
50. Gupta S. Ramjaun A.R. Haiko P. Wang Y. Warne P.H. Nicke B. et al. (2007) Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957–968.
51. Halilovic E. She Q.B. Ye Q. Pagliarini R. Sellers W.R. Solit D.B. et al. (2010) PIK3CA mutation uncouples tumor growth and cyclin D 1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70: 6804–6814.
52. Han E.K. Leverson J.D. McGonigal T. Shah O.J. Woods K.W. Hunter T. et al. (2007) Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC 1 inhibition. Oncogene 26: 5655–5661.
53. Han J. Luby-Phelps K. Das B. Shu X. Xia Y. Mosteller R.D. et al. (1998) Role of substrates and products of PI 3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav. Science 279: 558–560.
54. Haruta T. Uno T. Kawahara J. Takano A. Egawa K. Sharma P.M. et al. (2000) A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. Mol Endocrinol 14: 783–794.
55. Hers I. Vincent E.E. Tavare J.M. (2011) Akt signalling in health and disease. Cell Signal 23: 1515–1527.
56. Hideshima T. Catley L. Yasui H. Ishitsuka K. Raje N. Mitsiades C. et al. (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053–4062.
57. Huang W.C. Hung M.C. (2009) Induction of Akt activity by chemotherapy confers acquired resistance. J Formos Med Assoc 108: 180–194.
58. Hung K.E. Maricevich M.A. Richard L.G. Chen W.Y. Richardson M.P. Kunin A. et al. (2010) Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment. Proc Natl Acad Sci U S A 107: 1565–1570.
59. Ihle N.T. Lemos R. Jr Wipf P. Yacoub A. Mitchell C. Siwak D. et al. (2009) Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69: 143–150.
60. Ihle N.T. Powis G. Kopetz S. (2011) PI-3-kinase inhibitors in colorectal cancer. Curr Cancer Drug Targets 11: 190–198.
61. Ikenoue T. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562–4567.
62. Ikenoue T. Kanai F. Hikiba Y. Obata T. Tanaka Y. Imamura J. et al. (2005) Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562–4567.
63. Jacinto E. Facchinetti V. Liu D. Soto N. Wei S. Jung S.Y. et al. (2006) SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 127: 125–137.
64. Jia S. Liu Z. Zhang S. Liu P. Zhang L. Lee S.H. et al. (2008) Essential roles of PI (3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776–779.
65. Kang S. Denley A. Vanhaesebroeck B. Vogt P.K. (2006) Oncogenic transformation induced by the p110beta, -gamma, and -delta isoforms of class I phosphoinositide 3-kinase. Proc Natl Acad Sci U S A 103: 1289–1294.
66. Karapetis C.S. Khambata-Ford S. Jonker D.J. O'Callaghan C.J. Tu D. Tebbutt N.C. et al. (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757–1765.
67. Katso R. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615–675.
68. Katso R. Okkenhaug K. Ahmadi K. White S. Timms J. Waterfield M.D. (2001) Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol 17: 615–675.
69. Kim H.H. Sierke S.L. Koland J.G. (1994) Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erb B 3 gene product. J Biol Chem 269: 24747–24755.
70. Kobayashi M. Nagata S. Iwasaki T. Yanagihara K. Saitoh I. Karouji Y. et al. (1999) Dedifferentiation of adenocarcinomas by activation of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A 96: 4874–4879.
71. Kodaki T. Woscholski R. Hallberg B. Rodriguez-Viciana P. Downward J. Parker P.J. (1994) The activation of phosphatidylinositol 3-kinase by Ras. Curr Biol 4: 798–806.
72. Kondapaka S.B. Singh S.S. Dasmahapatra G.P. Sausville E.A. Roy K.K. (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2: 1093–1103.
73. Langlois M.J. Roy S.A. Auclair B.A. Jones C. Boudreau F. Carrier J.C. et al. (2009) Epithelial phosphatase and tensin homolog regulates intestinal architecture and secretory cell commitment and acts as a modifier gene in neoplasia. FASEB J 23: 1835–1844.
74. Lee D. Yu M. Lee E. Kim H. Yang Y. Kim K. et al. (2009) Tumor-specific apoptosis caused by deletion of the ERBB 3 pseudo-kinase in mouse intestinal epithelium. J Clin Invest 119: 2702–2713.
75. Li J. Yen C. Liaw D. Podsypanina K. Bose S. Wang S.I. et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.
76. Li X. Liu J. Gao T. (2009) beta-TrCP-mediated ubiquitination and degradation of PHLPP 1 are negatively regulated by Akt. Mol Cell Biol 29: 6192–6205.
77. Liu J. Stevens P.D. Gao T. (2011) mTOR-dependent regulation of PHLPP expression controls the rapamycin sensitivity in cancer cells. J Biol Chem 286: 6510–6520.
78. Liu P. Cheng H. Roberts T.M. Zhao J.J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8: 627–644.
79. Luo J. Field S.J. Lee J.Y. Engelman J.A. Cantley L.C. (2005) The p 85 regulatory subunit of phosphoinositide 3-kinase down-regulates IRS-1 signaling via the formation of a sequestration complex. J Cell Biol 170: 455–464.
80. Luo J. Manning B.D. Cantley L.C. (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4: 257–262.
81. Maehama T. Dixon J.E. (1998) The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273: 13375–13378.
82. Manning B.D. Cantley L.C. (2007) AKT/PKB signaling: navigating downstream. Cell 129: 1261–1274.
83. Marsh V. Winton D.J. Williams G.T. Dubois N. Trumpp A. Sansom O.J. et al. (2008) Epithelial PTEN is dispensable for intestinal homeostasis but suppresses adenoma development and progression after Apc mutation. Nat Genet 40: 1436–1444.
84. Nosho K. Kawasaki T. Ohnishi M. Suemoto Y. Kirkner G.J. Zepf D. et al. (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10: 534–541.
85. O'Reilly K.E. Rojo F. She Q.B. Solit D. Mills G.B. Smith D. et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.
86. Pacey S. Rea D. Steven N. Brock C. Knowlton N. Shand N. et al. (2004) Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor everolimus (E, RAD001) and gemcitabine (GEM) in patients (pts) with advanced cancers. J Clin Oncol 22 (14 Suppl.): 3120.
87. Park J. Leong M.L. Buse P. Maiyar A.C. Firestone G.L. Hemmings B.A. (1999) Serum and glucocorticoid-inducible kinase (SGK) is a target of the PI 3-kinase-stimulated signaling pathway. EMBO J 18: 3024–3033.
88. Parsons D.W. Wang T.L. Samuels Y. Bardelli A. Cummins J.M. de Long L. et al. (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
89. Philp A.J. Campbell I.G. Leet C. Vincan E. Rockman S.P. Whitehead R.H. et al. (2001) The phosphatidylinositol 3’-kinase p 85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 61: 7426–7429.
90. Pritchard C.P. Grady W.M. (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60: 116–129.
91. Punt C.J. Boni J. Bruntsch U. Peters M. Thielert C. (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14: 931–937.
92. Qiu Y. Kung H.J. (2000) Signaling network of the Btk family kinases. Oncogene 19: 5651–5661.
93. Rahmani M. Reese E. Dai Y. Bauer C. Payne S.G. Dent P. et al. (2005) Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK 1/2 inactivation and the generation of ceramide and reactive oxygen species. Cancer Res 65: 2422–2432.
94. Rajagopalan H. Bardelli A. Lengauer C. Kinzler K.W. Vogelstein B. Velculescu V.E. (2002) Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 418: 934.
95. Rhodes N. Heerding D.A. Duckett D.R. Eberwein D.J. Knick V.B. Lansing T.J. et al. (2008) Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res 68: 2366–2374.
96. Rodriguez-Viciana P. Warne P.H. Dhand R. Vanhaesebroeck B. Gout I. Fry M.J. et al. (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370: 527–532.
97. Roper J. Richardson M.P. Wang W.V. Richard L.G. Chen W. Coffee E.M. et al. (2011) The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PloS ONE 6: e25132.
98. Roy H.K. Olusola B.F. Clemens D.L. Karolski W.J. Ratashak A. Lynch H.T. et al. (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23: 201–205.
99. Ruiter G.A. Zerp S.F. Bartelink H. van Blitterswijk W.J. Verheij M. (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 14: 167–173.
100. Rusch V. Baselga J. Cordon-Cardo C. Orazem J. Zaman M. Hoda S. et al. (1993) Differential Expression of the Epidermal Growth Factor Receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53: 2379–2385.
101. Russo A. Bazan V. Agnese V. Rodolico V. Gebbia N. (2005) Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP 53CRC collaborative studies. Ann Oncol 16(Suppl. 4): iv44–iv49.
102. Sabatini D.M. (2006) mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 6: 729–734.
103. Salmena L. Carracedo A. Pandolfi P.P. (2008) Tenets of PTEN tumor suppression. Cell 133: 403–414.
104. Saltz L.B. (2010) Adjuvant therapy for colon cancer. Surg Oncol Clin N Am 19: 819–827.
105. Samuels Y. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
106. Samuels Y. Diaz L.A. Jr Schmidt-Kittler O. Cummins J.M. Delong L. Cheong I. et al. (2005) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7: 561–573.
107. Samuels Y. Wang Z. Bardelli A. Silliman N. Ptak J. Szabo S. et al. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
108. Segal N.H. Saltz L.B. (2009) Evolving treatment of advanced colon cancer. Annu Rev Med 60: 207–219.
109. Sequist L.V. Waltman B.A. Dias-Santagata D. Digumarthy S. Turke A.B. Fidias P. et al. (2011) Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26.
110. Shao J. Evers B.M. Sheng H. (2004) Roles of phosphatidylinositol 3’-kinase and mammalian target of rapamycin/p70 ribosomal protein S 6 kinase in K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 64: 229–235.
111. Shin K.H. Park Y.J. Park J.G. (2001) PTEN gene mutations in colorectal cancers displaying microsatellite instability. Cancer Lett 174: 189–194.
112. Simi L. Pratesi N. Vignoli M. Sestini R. Cianchi F. Valanzano R. et al. (2008) High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol 130: 247–253.
113. Sjoblom T. Jones S. Wood L.D. Parsons D.W. Lin J. Barber T. et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268–274.
114. Soltoff S.P. Carraway K.L. 3rd Prigent S.A. Gullick W.G. Cantley L.C. (1994) Erb B3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 14: 3550–3558.
115. Sos M.L. Fischer S. Ullrich R. Peifer M. Heuckmann J.M. Koker M. et al. (2009) Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A 106: 18351–18356.
116. Stambolic V. Suzuki A. de l.a. Pompa J.L. Brothers G.M. Mirtsos C. Sasaki T. et al. (1998) Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95: 29–39.
117. Steck P.A. Pershouse M.A. Jasser S.A. Yung W.K. Lin H. Ligon A.H. et al. (1997) Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.
118. Tan M.H. Mester J.L. Ngeow J. Rybicki L.A. Orloff M.S. Eng C. (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 18: 400–407.
119. Tewari K.S. Kyshtoobayeva A.S. Mehta R.S. Yu I.R. Burger R.A. Disaia P.J. et al. (2000) Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol 78: 130–136.
120. Tol J. Koopman M. Miller M.C. Tibbe A. Cats A. Creemers G.J. et al. (2009) Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents. Ann Oncol 21: 1006–1012.
121. Umekita Y. Ohi Y. Sagara Y. Yoshida H. (2000) Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 89: 484–487.
122. van Loon K. Venook A.P. (2011) Adjuvant treatment of colon cancer: what is next? Curr Opin Oncol 23: 403–409.
123. Vasudevan K.M. Barbie D.A. Davies M.A. Rabinovsky R. McNear C.J. Kim J.J. et al. (2009) AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 16: 21–32.
124. Velho S. Moutinho C. Cirnes L. Albuquerque C. Hamelin R. Schmitt F. et al. (2008) BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8: 255.
125. Vivanco I. Sawyers C.L. (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501.
126. Waite K.A. Eng C. (2002) Protean pten: form and function. Am J Hum Genet 70: 829–844.
127. Warfel N.A. Newton A.C. (2012) Pleckstrin homology domain leucine-rich repeat protein phosphatase (PHLPP): a new player in cell signaling. J Biol Chem 287: 3610–3616.
128. Wee S. Jagani Z. Xiang K.X. Loo A. Dorsch M. Yao Y.M. et al. (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69: 4286–4293.
129. Wee S. Wiederschain D. Maira S.M. Loo A. Miller C. de Beaumont R. et al. (2008) PTEN-deficient cancers depend on PIK 3CB. Proc Natl Acad Sci U S A 105: 13057–13062.
130. Weiss S. Nemunaitis J.J. Diaz-Lacayo M. Birch R. Ebrahimi B. Berdeaux D.H. et al. (2006) A phase 1 study of daily oral perifosine (P) and weekly gemcitabine (G). J Clin Oncol 24 (18 Supp.): 13084.
131. Welch H. Eguinoa A. Stephens L.R. Hawkins P.T. (1998) Protein kinase B and rac are activated in parallel within a phosphatidylinositide 3OH-kinase-controlled signaling pathway. J Biol Chem 273: 11248–11256.
132. Wolpin B.M. Mayer R.J. (2008) Systemic treatment of colorectal cancer. Gastroenterology 134: 1296–1310.
133. Wood L.D. Parsons D.W. Jones S. Lin J. Sjoblom T. Leary R.J. et al. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318: 1108–1113.
134. Yang Y. Iwanaga K. Raso M.G. Wislez M. Hanna A.E. Wieder E.D. et al. (2008) Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PloS ONE 3: e2220.
135. Yarden Y. Sliwkowski M.X. (2001) Untangling the Erb B signalling network. Nat Rev Mol Cell Biol 2: 127–137.
136. Yuan T.L. Cantley L.C. (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497–5510.
137. Zhao L. Vogt P.K. (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486–5496.
138. Zhou X.P. Loukola A. Salovaara R. Nystrom-Lahti M. Peltomaki P. de l.a. Chapelle A. et al. (2002) PTEN mutational spectra, expression levels, and subcellular localization in microsatellite stable and unstable colorectal cancers. Am J Pathol 161: 439–447.